Display options
Cite
Asnani S, Kunhiraman B, Jawa A, et al. Pioglitazone restores endothelial function in patients with type 2 diabetes treated with insulin. Metab Syndr Relat Disord. 2006;4(3):179-84doi: 10.1089/met.2006.4.179.
Asnani, S., Kunhiraman, B., Jawa, A., Akers, D., Lumpkin, D., & Fonseca, V. (2006). Pioglitazone restores endothelial function in patients with type 2 diabetes treated with insulin. Metabolic syndrome and related disorders, 4(3), 179-84. https://doi.org/10.1089/met.2006.4.179
Asnani, Sunil, et al. "Pioglitazone restores endothelial function in patients with type 2 diabetes treated with insulin." Metabolic syndrome and related disorders vol. 4,3 (2006): 179-84. doi: https://doi.org/10.1089/met.2006.4.179
Asnani S, Kunhiraman B, Jawa A, Akers D, Lumpkin D, Fonseca V. Pioglitazone restores endothelial function in patients with type 2 diabetes treated with insulin. Metab Syndr Relat Disord. 2006;4(3):179-84. doi: 10.1089/met.2006.4.179. PMID: 18370736.
Copy Download .nbib Format: NLM
Share it on

Metab Syndr Relat Disord. 2006;4(3):179-84. doi: 10.1089/met.2006.4.179.

Pioglitazone restores endothelial function in patients with type 2 diabetes treated with insulin.

Metabolic syndrome and related disorders

Sunil Asnani, Biju Kunhiraman, Ali Jawa, Donald Akers, David Lumpkin, Vivian Fonseca

Affiliations

  1. Department of Medicine/Section of Endocrinology, Tulane University Health Sciences Center, New Orleans, Louisiana., Department of Medicine, Veterans Affairs Medical Center, New Orleans, Louisiana.

PMID: 18370736 DOI: 10.1089/met.2006.4.179

Abstract

The primary aim of this study was to evaluate the effect of pioglitazone on endothelial function, as assessed by flow-mediated dilatation (FMD) nitroglycerine-induced dilatation (NID) in patients with type 2 diabetes mellitus treated with insulin. A randomized double-blind placebo-controlled trial involved 20 patients with insulin-treated type 2 diabetes. Patients received either pioglitazone 30 mg or placebo for 4 months. FMD, NID, and HbA1c were measured before and after 4 months of treatment. HbA1c decreased from 10.0 (+/- 2.3) to 8.4 (+/- 2.0) in the pioglitazone group, a statistically significant improvement in glycemic control (p = 0.018). HbA1c was unchanged in the placebo group (p = 0.477). Endothelial function as assessed by FMD significantly improved from 10.1 (+/- 4.0)% to 14.6 (+/- 6.2)% in the pioglitazone group (p = 0.036) as compared to the placebo group (p = 0.705). There was a trend towards improvement in the NID in the pioglitazone group (from 13.3 +/- 8.0% to 18.9 +/- 5.4%; p = 0.056). In insulin-treated patients with type 2 diabetes, the addition of pioglitazone improves endothelial function, as measured by FMD. Addition of pioglitazone to insulin in type 2 diabetes patients may favorably impact vascular function in diabetes, even after many years of insulin resistance and hyperglycemia.

Publication Types